Abstract 3351
Background
Microsatellite instability (MSI) is observed in 15% of all colorectal cancers (CRC), including Lynch syndrome caused by germline mutation of an MMR gene. Guidelines recommend assessing the MSI status of all CRC patients for screening for Lynch syndrome as well as for prognostic stratification. MSI-high tumors are more vulnerable to the immune system and therefore generally have a better prognosis.
Methods
The performance of the Idylla™ MSI Assay was compared to routine immunohistochemistry (IHC) and molecular tests (including Bethesda panel) on 1,301 archival CRC formalin-fixed, paraffin-embedded (FFPE) tissue sections, at 44 centers worldwide.
Results
The failure rate of the Idylla™ MSI Assay was 0.23%, while the molecular methods had a higher failure rate overall of 0.86% probably due to their use of a longer amplicon. IHC had a much higher failure rate of 4.37%, possibly related to interpretation difficulties of the results. Routine method failure rates might be an underestimation as the current analysis was done retrospectively on samples with known routine results. Compared to IHC, the results of 37 of the 1,075 samples tested were discordant, resulting in an overall concordance agreement of 96.6%. When taking molecular results and further analysis of discordant samples into account, the Idylla™ MSI result was confirmed in 16 samples. Compared to molecular methods, 16 of the 812 samples tested were discordant, resulting in an overall concordance agreement of 98.0%. Taking IHC results and further analysis of discordant samples into account, the Idylla™ MSI result was confirmed in 8 samples.
Conclusions
Results of the Idylla™ MSI Assay were highly concordant with results of routine tests and lower failure rates were observed. Further advantages are the lack of need for matched normal tissue, the low dependence on pre-analytical conditions, the simplified workflow, the short turnaround times, the automated result interpretation, and the very limited hands-on work.
Clinical trial identification
Editorial acknowledgement
Teams involved in the MSI, Idylla MSI Assay, Colon Rectal Cancer, Multicenter Study.
Legal entity responsible for the study
Irblleida.
Funding
Biocartis.
Disclosure
X. Matias-guiu: Non-remunerated activity/ies: Biocartis.
Resources from the same session
5612 - Evaluation of germ line mutational status among women with triple-negative breast cancer in Russia
Presenter: Elena Shagimardanova
Session: Poster Display session 2
Resources:
Abstract
4142 - Association of derived neutrophil-to-lymphocyte ratio (dNLR) with pathological complete response (pCR) after neoadjuvant chemotherapy (CT)
Presenter: Alberto Ocaña
Session: Poster Display session 2
Resources:
Abstract
1733 - Competing nomogram for late-period breast cancer-specific death in patients with early-stage hormone receptor-positive breast cancer
Presenter: Jianfei Fu
Session: Poster Display session 2
Resources:
Abstract
1978 - A Nomogram to Predict Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Blood Indicators
Presenter: Fanrong Zhang
Session: Poster Display session 2
Resources:
Abstract
3062 - Identification of GSTP1 transferred by extracellular vesicles responsible for adriamycin-resistance in breast cancer cells
Presenter: Sujin Yang
Session: Poster Display session 2
Resources:
Abstract
5274 - Expression of X-linked Inhibitor of Apoptosis Protein (XIAP) and its Association with Clinicopathological Parameters in Invasive Breast Cancers
Presenter: Gayathri Devi
Session: Poster Display session 2
Resources:
Abstract
1324 - The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients
Presenter: Soo Youn Bae
Session: Poster Display session 2
Resources:
Abstract
4877 - Correlation of clinical and pathological features with the tumour microenvironment in DCIS. An institutional experience
Presenter: Ann Eapen
Session: Poster Display session 2
Resources:
Abstract
2471 - Correlation between radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer and pathologic complete response and their impact in recurrence-free survival
Presenter: Ariadna Gasol Cudos
Session: Poster Display session 2
Resources:
Abstract
2632 - Ring-like uptake appearance on dedicated breast positron emission tomography before chemotherapy predicts outcome of neoadjuvant chemotherapy in breast cancer
Presenter: Norio Masumoto
Session: Poster Display session 2
Resources:
Abstract